摘要
目的:为药物的临床应用提供参考,促进临床安全、合理用药。方法:根据我们观察到的2009～2010年使用参麦注射液与参附注射液不良反应(事件)ADR(E)病例报告及用药情况计算ADR(E)发生率、相对危险度(RR)、标准化报告比(SRR)、报告率比(ARRR)、用药频度(DUI、DDDs)等分析安全性、合理性。结果:参麦注射液与参附注射液ADR(E)发生率分别为0.619,0.686;RR分别为2.3,0;SRR与ARRR均≈1;DUI均≤1.0,DDDS分别为9700,10175。结论:参麦注射液与参附注射液使用安全、合理,两药安全性差异无统计学意义。
Objective： To provide references for clinical application of TCM and promote the safety and rational use of drugs. Methods ： Through ADR cases reports and the annual using information of Shenmai Injection and Shenfu Injection in 2009 -2010 we observed, analyzing the safety and the rational use by ADR （E） rates, RR, SRR, ARRR, DUI and DDDS. Results： ADR （E） rate were 0. 619 and 0. 686; RR were 2. 3 and 0; SRR and ARRR were about 1 ; both of DUI were less than 1.0, DDDS were 9700 and 10175, Conclusion： The two drugs are proved safe and reasonable. There are no significant differences for safety between the two drugs.
出处
《四川中医》
2012年第6期55-56,共2页
Journal of Sichuan of Traditional Chinese Medicine
